Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 1

Interventions

Paclitaxel 5liposomal doxorubicin 4Topotecan 3Doxorubicin 2Carboplatin 2Bevacizumab 2saracatinib 1pegfilgrastim 1olaparib 1cediranib 1atezolizumab 1Taxes 1Poly(ADP-ribose) Polymerase Inhibitors 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Ifosfamide 1Gemcitabine 1Disulfides 1Diathermy 1Chemotherapy, Adjuvant 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Fallopian Tube Neoplasms × 1-dodecylpyridoxal × Clear all
NCT06161025 2026-05-22

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Daiichi Sankyo

Phase 2/3 Recruiting
860 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡